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ABSTRAcT
 
Objectives: To ascertain the opinions of North American genitourinary (GU) experts 
regarding inclusion of technologies such as prostate - specifi c membrane antigen 
(PSMA) and C - 11 choline positron emission tomography (PET) into routine practice.
Materials and Methods: A survey was distributed to North American GU experts. Ques-
tions pertained to the role of PSMA and C - 11 PET in PCa management. Participants 
were categorized as “supporters” or “opponents” of incorporation of novel imaging 
techniques. Opinions were correlated with practice patterns.
Results: Response rate was 54% and we analyzed 42 radiation oncologist respondents. 
17 participants (40%) have been in practice for > 20 years and 38 (90%) practice at 
an academic center. 24 (57%) were supporters of PSMA and 29 (69%) were supporters 
of C - 11. Supporters were more likely to treat pelvic nodes (88% vs. 56%, p < 01) and 
trended to be more likely to treat patients with moderate or extreme hypofractionation 
(58% vs. 28%, p = 065). Supporters trended to be more likely to offer brachytherapy 
boost (55% vs. 23%, p = 09), favor initial observation and early salvage over adjuvant 
radiation (77% vs. 55%, p = 09), and to consider themselves expert brachytherapists 
(69% vs. 39%, p = 09).
Conclusions: There is a polarization among GU radiation oncology experts regarding 
novel imaging techniques. A correlation emerged between support of novel imaging 
and adoption of treatment approaches that are clinically superior or less expensive. Pre 
- existing biases among GU experts on national treatment - decision panels and leaders 
of cooperative group studies may affect the design of future studies and infl uence the 
adoption of these technologies in clinical practice.
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INTRODUcTION
Prostate cancer (PCa) is the most common 
malignancy in men. Primary management strate-
gies for PCa include surgery or radiation therapy 
(RT). Despite modern surgical and radiation tech-
niques, biochemical recurrence (BCR) rates remain 
relatively high, approaching 20 - 40% regardless 
of management technique (1-3). The ability to de-
tect ever lower levels of prostate-specifi c antigen 
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(PSA) has improved the ability to identify BCR, 
but localizing the cells that are producing PSA 
is not straightforward. Imaging in the setting of 
recurrent prostate cancer is notoriously challen-
ging. Commonly used imaging modalities such as 
computed tomography (CT) and fluorodeoxyglu-
cose positron - emission topography (FDG - PET) 
have low sensitivity for local recurrence and 
small metastases (4). Even technetium - 99 bone 
scans, the gold standard for detecting osseous 
metastases in men with prostate cancer, perform 
poorly in patients with low PSA. A positive bone 
scan in the absence of high - risk factors is more 
likely to be a false positive (5). Unfortunately, 
once the PSA is high enough for detection by 
traditional methods, the window for clinical in-
tervention may have closed.
 These challenges have led to an interest 
in radionuclides that can identify an actionable 
recurrence earlier in the disease course. Novel PET 
tracers such as C - 11 choline and gallium - 68 la-
belled prostate specific membrane antigen (PSMA) 
have shown promise in early detection of small 
foci of recurrent disease, both local and distant, in 
patients with BCR (6-8). Remarkably, PSMA has 
been able to localize recurrent disease (for lymph 
node involvement) with sensitivity and specificity 
of 94% and 99%, respectively, even at a low PSA 
(9). C - 11 choline has shown similarly encoura-
ging results, with recurrences detected at PSA le-
vels < 1 ng / mL (10, 11).
 A recent review of the clinical utility of 
prostate cancer-specific PET radiotracers has in-
dicated that PSMA is the most sensitive of the 
currently clinically evaluated prostate radiotra-
cers (12).
 The National Comprehensive Cancer Ne-
twork (NCCN) in 2017 recommended consideration 
of C - 11 PET in the setting of detectable PSA af-
ter prostatectomy, BCR after definitive RT, and in 
patients without metastases who are on androgen 
- deprivation therapy (ADT) with a rising PSA. It 
did not make recommendations regarding the use 
of PSMA. What is not known, however, is whe-
ther novel imaging techniques are being adopted 
into routine practice. Genitourinary (GU) oncolo-
gy experts, such as those who serve on decision 
- making committees of cooperative group resear-
ch organizations, lead the field in evidence - ba-
sed investigation and adoption of new diagnostic 
and therapeutic techniques. They also tend to be 
positioned at large, tertiary - care and academic 
medical institutions where novel radionuclides are 
more likely to be available. In this study, we seek 
to query GU oncology experts to assess the opi-
nions and trends of utilization of novel imaging 
techniques.
MATERIALS AND METHODS
Survey design and deployment
 The survey was designed to identify cha-
racteristics of each respondent’s typical practice 
patterns, as well as to assess their knowledge about 
and personal opinions on the role of PSMA and C - 
11 choline PET in PCa management. Eighty - eight 
currently practicing North American GU oncolo-
gy experts, who serve on cooperative group rese-
arch organizations such as NRG Oncology, were 
contacted by email and invited to complete our 
survey. The survey was designed and hosted by 
Research Electronic Data Capture (REDCap) (13). 
The survey contained screening questions to en-
sure respondents were currently practicing, not in 
training, and specialize in GU oncology. The study 
was approved by the institutional review board. A 
copy of the survey is available in the Supplemen-
tary Material.
Selection of practice pattern questions
 Topics for inclusion were selected based 
on their controversy within the field of radiation 
oncology. Many of the practices in question, des-
pite having been studied in large phase III rando-
mized trials, are points of divisiveness amongst 
radiation oncologists and serve as branch points 
for practice patterns. For example, moderate hy-
pofractionation has been proven to be noninferior, 
safe, and more economical than standard fractio-
nation (14), however many experts are still slow to 
adopt this practice. Pelvic lymph node irradiation 
is notoriously controversial in radiation oncology 
(15), and adjuvant vs. early salvage postoperative 
radiation is an area of evolving study (16).
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Statistical analysis
 Descriptive statistical analysis was con-
ducted to describe characteristics of respon-
dents. Participants were categorized as “suppor-
ters” or “opponents” of incorporation of novel 
imaging techniques into routine practice, with 
support of C - 11 choline PET and PSMA PET 
analyzed separately. Opinions regarding novel 
imaging were correlated with practice patterns 
using Fisher’s exact test. McNemar’s test was 
used to test the differences in distribution for 
supporting C - 11 choline and for supporting 
PSMA PET among respondents.
RESULTS
Respondents
 We received 48 responses for a response 
rate of 54%. For comparative studies, we limited 
our analysis to 42 radiation oncologist respon-
dents. Seventeen participants (40%) have been in 
practice for > 20 years and 38 (90%) practice at 
an academic center. Nineteen participants (45%) 
see > 20 patients / month in consultation. Twen-
ty - two respondents (52%) see an even balance 
of intact prostate and post - prostatectomy pa-
tients, and 17 (40%) see primarily intact prostate 
patients. The majority of respondents (35, 83%) 
perform a digital rectal examination (DRE) prior 
to treatment and half of respondents felt that 
DRE changes management. Twenty - five res-
pondents (60%) consider themselves to be expert 
brachytherapists.
Practice characteristics
 The majority of participants (40, 95%) 
recommend active surveillance for patients with 
Gleason 6 disease, and a few (7, 17%) recommend 
it for Gleason 3 + 4 disease. Most respondents (29, 
69%) often treat pelvic lymph nodes in patients 
with localized high risk disease. There was a fair-
ly even split (55% vs. 45%) between whether res-
pondents recommend adjuvant RT or observation 
and early salvage RT, respectively, for patients 
with high risk features. In a similar pattern, 45% 
of respondents recommended the addition of a 
brachytherapy boost for patients with high risk 
disease and no baseline urinary symptoms, whi-
le the remaining 55% would recommend external 
beam radiation and ADT alone. Regarding dose 
and fractionation, 23 (55%) consider standard 
fractionation (78 Gy in 2 Gy fractions or equiva-
lent) to be the default for a patient with Gleason 
3 + 4 disease. Seventeen (40%) chose moderate 
hypofractionation (70 Gy in 2.5 Gy fractions or 
equivalent) as the default, and two (5%) chose ste-
reotactic body radiation therapy (SBRT) / radical 
hypofractionation (5 - 12 fractions). A summary 
of practice characteristics is provided in Table-1.
Novel imaging
 Twenty - seven respondents (60%) were 
already aware that the NCCN recommends consi-
deration of C - 11 PET for patients with prostate 
cancer. The NCCN guidelines were then presented 
to respondents. Following this, a series of ques-
tions was posed to ascertain whether respondents 
agreed with the NCCN recommendations or whe-
ther they felt C - 11 or PSMA PET should be re-
commended in more or fewer situations than the 
current guidelines dictate. Opponents were defined 
as those who answered that novel imaging tech-
niques should not be recommended by the NCCN 
in any situations due to a lack of evidence. Sup-
porters were defined as those who answered that 
novel imaging should be recommended in at least 
some scenarios. Twenty - four (57%) were suppor-
ters of PSMA PET and 29 (69%) were supporters of 
C - 11 PET. Regarding the comparison between the 
two techniques, the majority (27, 66%) feel that 
there is not enough evidence to know whether C - 
11 or PSMA PET is more effective. However, some 
respondents did rank one test above the other, 
with 27% and 5% answering PSMA PET and C - 
11 PET, respectively.
 Even in a group of experts who primarily 
practice at academic centers, the majority of res-
pondents (26, 63%) do not have either C - 11 or 
PSMA PET available at their institution (Figure-1). 
Of those who do have the tests available (Figu-
re-2), 6 (40%) routinely order them for patients, 
and 8 (53%) order them on rare occasion. Of those 
who do not have the tests available (Figure-3), 15 
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(58%) refer patients to centers capable of perfor-
ming them. Six (23%) do not refer, but will use the 
results to guide decision - making if the patient 
previously underwent imaging. The remaining 
19% do not refer and do not use the tests to guide 
decision - making. When asked for reasons why 
they do not order PSMA or C - 11 PET more often, 
providers most frequently answered availability 
(31, 74%). The second most common reasons were 
cost (18, 43%) and lack of evidence (15, 36%). Se-
ven respondents (17%) answered that they do not 
order the scans because they are unsure how to 
interpret them.
Patterns of practice in novel imaging supporters
 Supporters of PSMA PET were more likely 
than opponents of PSMA PET to routinely treat 
pelvic nodes in patients with high risk PCa (88% 
vs. 44%, Fisher’s exact p < 01) and trended to be 
more likely to treat patients with low/intermediate 
PCa with moderate (20 - 28 fractions) or extre-
me (5 - 15 fractions) hypofractionation (58% vs. 
Table 1 - Practice characteristics.
GU Expert Practice Recommendation (n = 42) Participants selecting response n (%)
Active Surveillance (AS)
Recommend AS for GS 6 40 (95)
Recommend AS for GS 3 + 4 7 (17)
Management of oligometastatic Pca
Offer SBRT to oligometastatic patient outside of clinical trial 32 (76)
Prophylactic pelvic irradiation
Treat pelvis in localized high risk patients 29 (69)
Management of pT3 disease after RP
Recommend adjuvant RT for high risk operative patients 23 (55)
Recommend observation and early salvage RT for high risk operative patients 19 (45)
Management of High Risk Pca
Recommend EBRT and ADT 23 (55)
Recommend brachy boost with EBRT and ADT 19 (45)
Fractionation scheme for low / intermediate risk
Recommend standard fractionation (i.e. 1.8-2Gy / fx) 23 (55)
Recommend moderate hypofractionation (i.e. 2.5 - 3Gy / fx) 17 (40)
Recommend SBRT / radical hypofractionation 2 (5)
Management of low risk Pca patient who desires treatment
Recommend EBRT 7 (17)
Recommend brachytherapy 21 (50)
Recommend either EBRT or brachytherapy 14 (33)
GU = genitourinary oncology; Pca = prostate cancer; GS = Gleason score; SBRT = stereotactic body radiation therapy; RT = radiation therapy; ADT = androgen deprivation therapy
IBJU | cLInIcAL APPLIcAtIon oF Pet IMAGInG In PRostAte cAnceR AMonG eXPeRts
27
28%, Fisher’s Exact p = 065). Supporters of C - 11 
PET trended to be more likely than opponents of 
C - 11 PET to offer to patients with high risk PCa 
brachytherapy boost (55% vs. 23%, Fisher’s exact 
p = 09), favor initial observation and early salva-
ge over adjuvant radiation in patients with high 
risk features after prostatectomy (55% vs. 23%, 
Fisher’s exact p = 09), and to consider themsel-
ves expert brachytherapists (69% vs. 38%, Fisher’s 
Exact p = 09). Table-2 demonstrates the distribu-
tion of supporters of C - 11 compared with PSMA 
PET, revealing an overall trend to either suppor-
ting or opposing both agents, with very few res-
pondents showing selectivity for PSMA (2 out of 
42) or C - 11 (7 out of 42).
DIScUSSION
 Molecular imaging is a rapidly evolving 
fi eld that is poised to change the paradigm for 
Figure 1 - Pie chart demonstrating the number of respondents 
who have at their institution c - 11 PET, PSMA PET, both of 
these, or neither.
Figure 2 - Of respondents who answered they have c - 11 PET, PSMA PET, or both available at their institution, what is the 
current practice for their use?
C-11 PET
do not order or use results
PSMA PET
rarely order but will use results routinely order and use results
routinely order and use results
rarely order but will use results
do not order or use results
Neither
Neither
26
63.41%
Both
7
17.07%
6
40.00%
C-11 PET
5
12.20%
1
6.67%
PSMA PET
3
  7.32%
8
53.33%
Both
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how BCR in PCa is managed. However, with the 
abundance of data revealed by each scan and with 
new research constantly emerging, it can be chal-
lenging to determine if and when these imaging 
techniques should be employed. In this study, we 
surveyed a group of highly specialized GU onco-
logy experts who serve on decision - making com-
mittees of collaborative group research organiza-
tions regarding their opinions and usage of C - 11 
choline and PSMA PET. To our knowledge, this 
study is the fi rst of its kind to ascertain expert opi-
nion on the topic and to correlate those opinions 
with practice characteristics.
 A rising PSA after defi nitive therapy in a 
patient who otherwise has no evidence of PCa re-
presents a therapeutic challenge. Practitioners ty-
pically use a variety of factors such as PSA level, 
PSA doubling time, Gleason score, and margin 
status to predict whether a patient’s recurrence is 
local or distant. While local salvage therapy does 
Figure 3 - Of respondents who answered they do not have either c - 11 PET or PSMA PET available at their institution, what 
is the current practice for referral?
Table 2 - Distribution of supporters of c - 11 compared with PSMA PET.
C - 11 Supporter C - 11 Opponent Total
PSMA Supporter 22 2 24
PSMA Opponent 7 11 18
Total 29 13 42
McNemar’s Test = p = 0.180
I often refer
I do not refer but will use results
I rarely refer
I do not refer or use results
6
23.08%
3
11.54%
12
46.15%
5
19.23%
I do not refer or use results
I often refer
I rarely refer
I do not refer but will use results
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improve outcomes and provide cure in some pa-
tients (17), men with a persistently elevated PSA 
or those who develop clinically evident metasta-
ses are sentenced to lifelong ADT and its myriad 
side effects. Treatment of a localized recurrence 
may have the potential to spare patients from this 
fate. An emerging area of interest in PCa, among 
other cancers, is the effort to slow disease pro-
gression and potentially offer cure in oligome-
tastatic patients. Though most reports have been 
from small series of patients, initial results are 
promising (18). One would surmise that iden-
tifying oligometastatic patients earlier with 
PSMA or C - 11 PET scans could both identify 
small metastases before they become widespre-
ad, as well as offer the benefit of a smaller and 
more safely ablatable target. In patients who 
have widespread metastases, PSMA ligand - ba-
sed radionuclide therapy is another potentially 
beneficial application of this technology. Small 
series have shown very encouraging results in 
terms of disease response and pain relief, with 
minimal toxicity (19, 20).
 Though the NCCN in 2017 made recom-
mendations for the use of C - 11 PET imaging, 
consensus groups have not released any official 
guidelines thus far. Providers unfamiliar with C 
- 11 choline or PSMA PET may struggle with de-
cision - making when presented with these scans. 
Patients with a low but detectable PSA with a 
single lesion on PSMA PET may desire definitive 
treatment, and providers may be eager to offer it, 
even without pathologic confirmation.
 With the available evidence thus far, GU 
oncology experts are split on whether or not 
to utilize novel imaging in treatment decision 
making. Interestingly, this split seems to follow 
along with a pattern of practice characteristics. 
Those experts who support practice strictly ac-
cording to randomized data, such as adding a 
brachytherapy boost for patients with high risk 
disease (21, 22) or using moderate hypofractiona-
tion (14, 23), also tend to support the use of novel 
imaging techniques. Supporters of novel imaging 
techniques were also more likely to treat pelvic 
lymph nodes in patients with high risk features, 
a technique which is more aggressive but has not 
been shown definitively to improve outcomes (24, 
25). Perhaps those practitioners who treat patients 
more aggressively, such as with a brachytherapy 
boost and pelvic nodal coverage, are more inte-
rested in novel imaging studies which would pro-
vide them with a therapeutic target in the setting 
of BCR. Regardless of the logic behind their de-
cision - making, the dichotomy that has emerged 
among participants in this survey has important 
implications. Our study suggests that, even in the 
face of future randomized evidence, GU oncology 
experts may remain divided over the appropria-
teness of inclusion of novel imaging in routine 
practice. It may also delay the implementation of 
therapy such as PSMA - ligand - based radionu-
clide therapy. Thus, the inherent biases of experts 
in large part shape the field of prostate cancer 
management.
 This study has several limitations, inclu-
ding those inherent to all survey studies as pre-
viously reported (26). Though we had a substan-
tial response rate of 54%, the absolute number of 
respondents are small, as we limited our target 
population only to GU oncology experts who ser-
ve on cooperative group research organizations. 
The small overall sample size also likely contribu-
ted to the difficulty with reaching the standard p 
< 0.05 cutoff for statistical significance for many 
comparisons. However, many of the differences 
we report are quite stark, with p values that trend 
toward significance. An additional limitation is 
that responses were multiple - choice and may 
not capture the full range of opinions. Survey 
fatigue can also result in responses that are not 
genuine, however there was not an incentive, fi-
nancial or otherwise, to complete the survey whi-
ch may improve the rate of legitimate responses. 
Though the initial results of novel radionuclide 
studies are promising, further research is still ne-
eded to confirm their accuracy. Pathologic confir-
mation with biopsy of distant metastatic disease 
or with sentinel lymph node biopsy in the case of 
radiographically positive lymph nodes (27) will 
add to the body of literature supporting these te-
chniques. Additionally, the value of early inter-
vention for oligometastatic patients has not yet 
been fully elucidated. Finally, because only 15 of 
41 responders had PET in their facilities (Figu-
re-1), there was a significant potential for origin 
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bias. It is also unclear regarding the familiarity 
of responders with both imaging methods, which 
could have influenced the final results of this study.
cONcLUSIONS
 There is a stark polarization among GU 
radiation oncology experts regarding the use of 
novel imaging techniques in routine practice. Mo-
reover, there appears to be a correlation between 
support of novel imaging and adoption of treat-
ment approaches shown in randomized trials to 
be either clinically superior or less expensive. Pre 
- existing biases regarding novel imaging among 
GU experts on national treatment - decision pa-
nels and leaders of cooperative group studies may 
affect the design of future clinical studies and 
influence the adoption of these technologies in 
clinical practice. The support of novel imaging 
techniques among the community of GU experts 
would open a multitude of possibilities for resear-
ch in this area.
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